Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 24 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 19
States / cities: Los Angeles, California • San Diego, California • Jacksonville, Florida + 13 more

Conditions: Congestive Heart Failure
Interventions: Carvedilol; Drug
Lead sponsor: Shaddy, Robert, M.D.; Individual
Eligibility: 1 Day to 17 Years
Enrollment: 75 participants
Timeline: 2002 – 2006
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 13 more

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 6 more

Conditions: HIV Infections
Interventions: Treatment Interruption; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • Cincinnati, Ohio + 2 more

Conditions: HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions: Topotecan; Drug
Lead sponsor: SmithKline Beecham; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 2 more

Conditions: HIV Infections
Interventions: Saquinavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Sherman Oaks, California + 6 more

Conditions: HIV Infections
Interventions: VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 7
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 2 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 14 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Efavirenz; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 5 more

Conditions: HIV Infections
Interventions: Daily dosing, Time-driven dosing, Event-driven dosing; Drug
Lead sponsor: HIV Prevention Trials Network; Network
Eligibility: 18 Years and older
Enrollment: 622 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Terbinafine hydrochloride; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Fort Lauderdale, Florida • Fort Myers, Florida • Tamarac, Florida + 6 more

Conditions: Cocaine-Related Disorders, Drug Administration Schedule, Infusions, Intravenous
Interventions: Modafinil; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: HIV Infections
Interventions: Abacavir sulfate, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 28 Days
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 8 more

Conditions: HIV Infections
Interventions: Indinavir sulfate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 1,900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 14
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 10 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 22
States / cities: Birmingham, Alabama • San Francisco, California • Denver, Colorado + 12 more

Conditions: Amphetamine-related Disorders
Interventions: contingency management voucher; Behavioral
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Los Angeles, California • Rancho Cucamonga, California

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 15
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Congestive Heart Failure
Interventions: carvedilol, placebo; Drug
Lead sponsor: Shaddy, Robert, M.D.; Individual
Eligibility: 1 Day to 17 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Emtricitabine, Stavudine; Drug
Lead sponsor: Triangle Pharmaceuticals; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more

Conditions: Diabetes Mellitus, Type 2, Medication Adherence
Interventions: UMS Strategy, SMS Text Messaging; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Dapsone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Month to 12 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 43
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 29 more

Conditions: Alcohol Withdrawal Syndrome
Interventions: Lorazepam (drug), Lorazepam; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: HIV Infections
Interventions: lopinavir/ritonavir, emtricitabine, stavudine, tenofovir DF; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 27
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 20 more

Search by objective public record fields.

Zidovudine and Lamivudine Given Once Versus Twice Daily

Study to Evaluate the Safety of Twice Daily Oral Carvedilol

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the Body

Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)

A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients

Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz

The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)

Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

Evaluation of Modafinil as a Cocaine Treatment Medication and Interactions With Cocaine - 1

A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women

The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients

A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection

Long-term Behavior Change - 1

Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048

Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

Regimen Education and Messaging in Diabetes (REMinD)

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

Treatment of Alcohol Withdrawal in Hospital Patients

A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation